Education
About Us
Working with TipRanks
Follow Us
Compugen (CGEN)
:CGEN
Top Page
Compugen
(NASDAQ:CGEN)
52Neutral
Positive Factors
Clinical Trials
The company's current valuation reflects increased potential due to seven ongoing Phase 3 trials for the TIGIT x PD-1 bispecific rilvegostomig.
Partnerships
Compugen is eligible for up to $200M in development and commercialization milestones spread across the first two rilvegostomig indications, indicating strong partnership benefits.
Safety Profile
Rilvegostomig's strong safety outcomes allow for combination with other toxic therapies, potentially enhancing its therapeutic range.
Negative Factors
Financial Reserves
Compugen ended the year with $103.3M in cash, equivalents, and short-term investments, which may be considered limited for sustaining long-term trials without additional funding.
Investor Awareness
Investors are missing the positive data in NSCLC and gastric cancer from Compugen's partner, AZN, which could limit stock appreciation.
Compugen (CGEN) vs. S&P 500 (SPY)
Market Cap
$143.07M
Dividend YieldN/A
Average Volume (3M)325.25K
Price to Earnings (P/E)87.5
Beta (1Y)2.25
Revenue Growth-16.72%
EPS Growth26.35%
CountryUS
Employees74
SectorHealthcare
Sector Strength72
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding93,512,985
10 Day Avg. Volume231,395
30 Day Avg. Volume325,251
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.00Price Target Upside173.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Compugen Business Overview & Revenue Model
Company DescriptionCompugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
How the Company Makes MoneyCompugen makes money through a combination of strategic partnerships, collaborations, and licensing agreements with pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments based on the progress of drug development, and royalties from sales of successfully commercialized therapies. Additionally, the company may receive research and development funding from its partners to advance its drug candidates through various stages of clinical trials. Compugen's revenue model relies heavily on the success of its drug discovery platform in identifying viable immuno-oncology targets and the subsequent commercialization of these discoveries.
Compugen Financial Statement Overview
Summary
Compugen's financial performance reflects the challenges typical in the biotechnology sector, with fluctuating revenues, consistent profitability issues, and improved cash flow management. While cash flow shows improvement, ongoing net losses and financial volatility suggest caution.Income Statement
Compugen has shown fluctuating revenue growth, with a positive increase from 2021 to 2023 but a decline in 2024. The consistent negative net income and EBIT margins reflect ongoing challenges in profitability, typical in the biotechnology sector. Despite improvements in gross profit, the company's net profit margins remain negative, indicating operational inefficiencies.50
Neutral
Balance Sheet
The balance sheet reveals a stable equity position but high volatility in debt levels. The debt-to-equity ratio remains low, suggesting manageable leverage. However, the declining equity ratio and fluctuations in stockholders' equity indicate potential risks in maintaining financial stability.55
Neutral
Cash Flow
Cash flow analysis shows significant improvement in operating cash flow and free cash flow by 2024, highlighting better cash management. However, the company experienced negative free cash flow in previous years, raising concerns about long-term cash sustainability. The positive cash flow trend in 2024 is a promising sign of recovery.60
Neutral
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 7.50M | 27.86M | 33.46M | 7.50M | 6.00M | 2.00M | Gross Profit |
| 6.53M | 19.93M | 31.45M | 6.53M | 5.32M | 1.94M | EBIT |
| -34.51M | -14.89M | -12.99M | -35.37M | -35.07M | -31.50M | EBITDA |
| -34.01M | -14.40M | -12.52M | -35.37M | -34.61M | -31.50M | Net Income Common Stockholders |
| -31.56M | -14.23M | -18.75M | -33.69M | -32.87M | -27.26M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 21.82M | 103.25M | 50.69M | 83.71M | 117.76M | 124.43M | Total Assets |
| 36.46M | 115.00M | 121.33M | 94.18M | 132.16M | 138.32M | Total Debt |
| 0.00 | 2.91M | 1.35M | 1.93M | 2.75M | 3.17M | Net Debt |
| -7.30M | -15.32M | -12.54M | -9.13M | -5.05M | -3.98M | Total Liabilities |
| 8.17M | 60.08M | 55.77M | 16.50M | 25.47M | 18.53M | Stockholders Equity |
| 28.29M | 54.91M | 65.56M | 77.68M | 106.69M | 119.78M |
| Cash Flow | Free Cash Flow | ||||
| -23.38M | 49.49M | -36.06M | -34.99M | -23.04M | -28.49M | Operating Cash Flow |
| -23.03M | 49.60M | -35.89M | -34.51M | -22.75M | -28.32M | Investing Cash Flow |
| 40.39M | -46.25M | 35.51M | 37.06M | 6.62M | -82.17M | Financing Cash Flow |
| -18.41M | 554.00K | 3.08M | 353.00K | 16.84M | 108.46M |
Compugen Technical Analysis
Negative
1.46
Price Trends
1.99
Negative
1.80
Negative
1.80
Negative
Market Momentum
-0.12
Negative
32.02
Neutral
16.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEN, the sentiment is Negative. The current price of 1.46 is below the 20-day moving average (MA) of 1.61, below the 50-day MA of 1.99, and below the 200-day MA of 1.80, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 32.02 is Neutral, neither overbought nor oversold. The STOCH value of 16.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CGEN.
Compugen Risk Analysis
Compugen disclosed 79 risk factors in its most recent earnings report. Compugen reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Compugen Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $7.24B | ― | -80.35% | ― | ― | -10.89% | |
52 Neutral | $143.07M | 87.50 | -23.63% | ― | -16.72% | 26.35% | |
50 Neutral | $137.40M | ― | -124.10% | ― | 9.22% | 60.01% | |
48 Neutral | $6.84B | 1.02 | -53.11% | 2.50% | 16.84% | 0.92% | |
42 Neutral | $97.33M | ― | -54.21% | ― | -78.55% | -0.92% | |
42 Neutral | $11.89M | ― | -151.46% | ― | -95.23% | -325.89% | |
39 Underperform | $243.53M | ― | -16.20% | ― | 498.72% | 49.92% |
* Healthcare Sector Average
Performance Comparison
CGEN
Compugen
1.46
-1.01
-40.89%
NKTR
Nektar Therapeutics
0.68
-0.22
-24.44%
MDGL
Madrigal Pharmaceuticals
331.23
75.49
29.52%
XOMA
Xoma
19.93
-5.32
-21.07%
FATE
Fate Therapeutics
0.79
-6.29
-88.84%
AFMD
Affimed
0.72
-5.63
-88.66%
Compugen Earnings Call Summary
Earnings Call Date: Mar 4, 2025 | % Change Since: -19.34% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements in Compugen's clinical programs, strategic partnerships, and financial stability, which are promising for future growth. However, the company faced revenue declines and a net loss, along with challenges in the TIGIT landscape. Despite these challenges, the strategic advances and strong financial position suggest a cautiously optimistic outlook.Highlights
Advancement of COM701
Data presented in 2024 showed that COM701, in combination with COM902 and pembrolizumab, resulted in encouraging durable responses in platinum-resistant ovarian cancer patients. The company plans to advance COM701 as a maintenance treatment for platinum-sensitive ovarian cancer, with a strategic trial set to start in Q2 2025.
Strategic Partnerships with AstraZeneca and Gilead
Compugen's collaboration with AstraZeneca for rilvegostomig (derived from COM902) includes seven Phase III trials, with potential milestone payments and royalties. Gilead licensed GS-0321, leading to a $30 million milestone payment in 2024 and the initiation of a Phase I trial.
Strong Financial Position
Compugen reported a cash balance of $103.3 million as of December 31, 2024, with a cash runway expected to last into 2027, supporting the company's operating plans and strategic initiatives.
Promising Results for GS-0321
Received FDA IND clearance and initiated a Phase I trial for GS-0321, an anti-IL-18 binding protein antibody, marking progress in their therapeutic pipeline.
Lowlights
Revenue Decline
Compugen reported $27.9 million in revenues for 2024, a decline from $33.5 million in 2023, primarily due to changes in milestone payments and licensing agreements.
Net Loss in 2024
The company reported a net loss of $14.2 million for the year ended December 31, 2024, compared to a net loss of $18.8 million in 2023, indicating ongoing financial challenges.
TIGIT Antibody Class Setbacks
There were several setbacks for the TIGIT antibody class, resulting in study discontinuations, leading to skepticism about the potential benefits of TIGIT blocker combinations.
Company Guidance
During Compugen's Fourth Quarter and Full Year 2024 Results Conference Call, the company provided guidance on several key metrics and strategic priorities for 2025. Compugen highlighted the advancement of COM701 as a maintenance treatment for platinum-sensitive ovarian cancer, with plans to initiate an adaptive platform trial in the second quarter of 2025. This trial will involve 60 patients and aims to demonstrate a clinically meaningful 3-month improvement in median progression-free survival over the expected 6-month benchmark of the placebo group. Interim analysis results are anticipated in the second half of 2026. Additionally, the company acknowledged setbacks in the TIGIT antibody class but emphasized ongoing Phase III trials with AstraZeneca involving COM902 and rilvegostomig. Compugen's financial position was also addressed, noting a cash balance of approximately $103.3 million as of December 31, 2024, and a cash runway extending into 2027. The company reported $27.9 million in revenues for 2024, with significant contributions from milestone payments related to GS-0321 and rilvegostomig. Research and development expenses decreased, reflecting changes in the classification of costs associated with GS-0321.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.